Avalo Therapeutics, Inc. (AVTX) Earnings History
Annual and quarterly earnings data from 2012 to 2025
Loading earnings history...
AVTX EPS Growth (CAGR)
Compound annual growth rate of diluted earnings per share
CAGR (Compound Annual Growth Rate) shows the annualized growth rate of EPS over the specified period. A higher CAGR indicates stronger earnings momentum.
AVTX Profitability Analysis
Margin trends over time
| Year | Gross Margin | Operating Margin | Net Margin |
|---|---|---|---|
| 2025 | 0.0% | -123601.7% | -132642.4% |
| 2024 | 183.0% | -15535.6% | -7965.8% |
| 2023 | 33.3% | -1421.6% | -1639.5% |
| 2022 | 81.0% | -207.4% | -230.8% |
| 2021 | 72.4% | -1521.6% | -1563.1% |
Download Data
Export AVTX earnings history in CSV or JSON format
Free sign-in required to download data
Avalo Therapeutics, Inc. (AVTX) Earnings Overview
As of May 8, 2026, Avalo Therapeutics, Inc. (AVTX) reported trailing twelve-month net income of -$78M, reflecting -79.1% year-over-year growth. The company earned $-5.84 per diluted share over the past four quarters, with a net profit margin of -132642.4%.
Looking at the long-term picture, AVTX's historical earnings data spans multiple years. The company achieved its highest annual net income of $12M in fiscal 2017.
Avalo Therapeutics, Inc. is currently reporting a net loss, though operating performance should be evaluated in the context of growth investments and industry dynamics View revenue history →
Compared to peers including IMVT (-$464M net income), ARQT (-$2M net income, -4.3% margin), KYMR (-$315M net income, -794.4% margin), AVTX has comparable earnings metrics. Compare AVTX vs IMVT →
AVTX Earnings vs Peers
Earnings metrics vs comparable public companies
AVTX Historical Earnings Data (2012–2025)
14 years| Fiscal Year | Net Income | YoY % | Operating Income | EPS (Diluted) | Net Margin | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | -$78M | -122.8% | -$73M | $-5.84 | -132642.4% | -123601.7% |
| 2024 | -$35M | -11.4% | -$69M | $-3.26 | -7965.8% | -15535.6% |
| 2023 | -$32M | +24.3% | -$27M | $-113.58 | -1639.5% | -1421.6% |
| 2022 | -$42M | +50.6% | -$37M | $-1062.65 | -230.8% | -207.4% |
| 2021 | -$84M | -32.9% | -$82M | $-2330.66 | -1563.1% | -1521.6% |
| 2020 | -$64M | -295.1% | $0 | $-2523.77 | -947.9% | 0.0% |
| 2019 | -$16M | +59.9% | -$16M | $-819.74 | -238.1% | -239.1% |
| 2018 | -$40M | -437.4% | -$39M | $-3317.28 | -218.5% | -214.5% |
| 2017 | $12M | +172.1% | $14M | $1822.74 | 42.7% | 49.9% |
| 2016 | -$16M | -57.0% | -$16M | $-21.93 | -1428.5% | -1394.6% |
See AVTX's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs AVTX Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare AVTX vs DBVT
Side-by-side business, growth, and profitability comparison vs DBV Technologies S.A..
Start ComparisonAVTX — Frequently Asked Questions
Quick answers to the most common questions about buying AVTX stock.
Is AVTX growing earnings?
AVTX EPS fell to $-5.84, with earnings declining -79.1%. This contrasts with the 5-year CAGR of N/A. TTM net income dropped to $-78M.
What are AVTX's profit margins?
Avalo Therapeutics, Inc. net margin is -132642.4%, with operating margin at -123601.7%. Below-average margins reflect competitive or cost pressures.
How consistent are AVTX's earnings?
AVTX earnings data spans 2012-2025. The declining earnings trend is -79.1% YoY. Historical data enables comparison across business cycles.